Anumana And Pfizer Team Up On AI-enabled ECG Algorithm For Detection Of Cardiovascular Disease

Digital News

Anumana and Pfizer team up on AI-enabled ECG algorithm for detection of cardiovascular disease

Anumana, an AI-driven health technology firm, has signed a multi year deal with Pfizer in order to develop an AI electrocardiogram (AI-ECG) for the early detection of cardiac amyloidosis.

Anumana will conduct a clinical validation trial in order to pursue de novo classification for the algorithm as a Software-as-a-Medical-Device (SaMD), with the aim to gain regulatory approval in the US, Europe and Japan.

For patients with cardiac amyloidosis, their heart walls become stiff: the left ventricle finds it difficult to relax to take in blood, while at the same time struggles to pump out blood within the heart. It is a serious, progressive and underdiagnosed rare disease that leads to heart failure.

This research agreement will help Anumana with its AI-enabled early detection software that can reveal signals from ECGs that humans cannot interpret.

Anumana chief business officer David McMullin said: “The challenge in diagnosing cardiac amyloidosis can prevent patients from getting treatment while the disease continues to progress. We believe this collaboration will demonstrate the power of Anumana’s AI-ECG algorithms to help clinicians intervene earlier, giving them greater ability to improve patient outcomes and prolong lives.”

“AI-ECG solutions alert clinicians to humanly imperceptible patterns in ECG signals, providing an early warning for serious occult or impending disease. This stands to improve the lives of people with cardiac amyloidosis by improving the speed of triage and care of this group,” stated Paul Friedman MD, chair of the Department of Cardiovascular Medicine at Mayo Clinic and chair of Anumana’s Mayo Clinic Board of Advisors.

Bristol Myers Squibb and Viz.ai sign multi-year partnership for HCM device

Bristol Myers Squibb and Viz.ai, an AI-powered medical imaging company, have signed a deal to use AI to detect and triage patients with suspected hypertrophic cardiomyopathy (hcm).

Sooma receives FDA Breakthrough Device designation for depression therapy device

Finnish company Sooma medical has received breakthrough device designation by the FDA for its portable, at-home neuromodulation device to treat depression.

Elon Musk’s Neuralink rejected by FDA for human trials

The FDA has reportedly rejected a bid by Elon Musk’s Neuralink in which it proposed the initiation of human testing for its brain chip implants. The company has been working on brain implants that allow for a computer-brain interface, which could allegedly restore vision to the blind and help paralysed people to walk again.

AI Finds Liver Cancer Drug Candidate In Only 30 Days

A team of scientists have broken records with their new AI which has found a novel drug candidate for liver cancer in only 30 days

DrugBAN AI Expected To Reduce Costs And Speed Up Drug Discovery

A new AI has been developed to deliver medicines at a faster rate and lower cost

Bristol Myers Squibb and Viz.ai sign multi-year partnership for HCM device

Sooma receives FDA Breakthrough Device designation for depression therapy device

Elon Musk’s Neuralink rejected by FDA for human trials

AI Finds Liver Cancer Drug Candidate In Only 30 Days

DrugBAN AI Expected To Reduce Costs And Speed Up Drug Discovery

Pharmafocus

Categories

Social Footprints